Alnylam Basks in the Glow of Heart Drugs Phase III Success on StockWatch

Alnylam Basks in the Glow of Heart Drugs Phase III Success on StockWatch ...

Onpattro, a drug that was approved first in Q1 2021, was worth $137.009 million in net product revenues, up 55% from $2306.081 million in 2020. Alnylam is one of several companies that is working on ATTR treatments that they hope will one day outperform the Pfizers' Vyndaqel and/ or Vyndamax.

Start Your 30-Day Free Trial Today.

Join GEN Edge and log in.

You may also like: